RxDoctor Payments Data

David Ancona, MD

Cardiovascular Disease · Pembroke Pines, FLNPI 1770579427

Payments from drug & device makers

$4,886in general payments, 2019–2025

Across 211 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Esperion Therapeutics, Inc.$610
  • Amarin Pharma, Inc.$570
  • Amgen$393
  • Novartis$354
  • Kowa Pharmaceuticals America, Inc.$298
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,84399%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,886 in reported general payments places this provider in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$193,180
Medicare patients
719
Services billed
2,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$74,461
EntrestoSacubitril/Valsartan49$69,279
JardianceEmpagliflozin62$68,696
XareltoRivaroxaban55$63,456
Repatha SureclickEvolocumab28$32,290
FarxigaDapagliflozin Propanediol12$12,477
NexlizetBempedoic Acid/Ezetimibe11$12,026
Nebivolol Hcl165$7,344
Rosuvastatin Calcium476$6,646
VascepaIcosapent Ethyl13$5,079
Ezetimibe165$4,787
Eplerenone61$4,518
Losartan Potassium451$4,318
Diltiazem 24hr Er (Cd)Diltiazem Hcl64$2,386
Diltiazem 24hr Er (La)Diltiazem Hcl17$1,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$193$74,46177 claims
NovartisEntresto$354$69,27949 claims
Boehringer IngelheimJardiance$1,258$68,69662 claims
Johnson & JohnsonXarelto$297$63,45655 claims
Esperion Therapeutics, Inc.Nexlizet$610$12,02611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →